Analyst Price Targets — CTRE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 16, 2026 8:13 pm | David Rodgers | Raymond James | $43.00 | $37.03 | TheFly | CareTrust REIT resumed with an Outperform at Raymond James |
| June 15, 2026 11:47 am | — | BMO Capital | $47.00 | $36.85 | TheFly | CareTrust REIT price target raised to $47 from $46 at BMO Capital |
| May 29, 2026 8:10 pm | — | KeyBanc | $46.00 | $40.82 | TheFly | CareTrust REIT price target raised to $46 from $40 at KeyBanc |
| May 22, 2026 10:41 am | Vikram Malhotra | Mizuho Securities | $45.00 | $41.01 | StreetInsider | CareTrust REIT (CTRE) PT Raised to $45 at Mizuho |
| February 24, 2026 1:51 pm | Michael Carroll | RBC Capital | $44.00 | $40.36 | TheFly | CareTrust REIT price target raised to $44 from $41 at RBC Capital |
| February 17, 2026 12:33 pm | — | Cantor Fitzgerald | $42.00 | $40.01 | TheFly | CareTrust REIT price target raised to $42 from $37 at Cantor Fitzgerald |
| January 22, 2026 7:34 am | — | Goldman Sachs | $44.00 | $37.39 | StreetInsider | Citizens Starts CareTrust REIT (CTRE) at Market Outperform |
| January 9, 2026 9:52 am | — | BMO Capital | $43.00 | $36.93 | TheFly | CareTrust REIT upgraded to Outperform from Market Perform at BMO Capital |
| January 8, 2026 11:29 am | — | UBS | $43.00 | $37.25 | TheFly | CareTrust REIT price target raised to $43 from $42 at UBS |
| December 15, 2025 9:47 pm | — | Jefferies | $43.00 | $36.59 | TheFly | CareTrust REIT price target raised to $43 from $41 at Jefferies |
Latest News for CTRE
Retirement income requires more than just high yield. REIT funds may not be the best solution. A balanced REIT portfolio can offer income and growth.
Healthcare REITs like Welltower are benefiting from aging demographics, rising senior housing demand and improving occupancy as new supply stays constrained.
DANA POINT, Calif.--(BUSINESS WIRE)--CareTrust REIT Announces Quarterly Dividend of $0.39 per Share.
CareTrust REIT remains fundamentally strong, but at a forward P/AFFO near 19.0x, I reiterate a hold rating, awaiting a deeper pullback. CTRE delivered robust Q1 results, with FFO up 14% year-over-year and raised 2024 guidance, yet growth may be moderating. Balance sheet strength is exceptional, with net debt/EBITDA at 0.6x and an upgrade to investment-grade, supporting future acquisition capacity.
The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CTRE.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.